CXCL16 and neoplasm: Pre-treatment with oxaliplatin and cyclophosphamide induced a pro-inflammatory tumor microenvironment and enhanced secretion of CCL5, CXCL9, CXCL10, and CXCL16 by tumor-infiltrating macrophages, leading to enhanced ROR1-CAR-T cell infiltration (60).